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ABSTRACT
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder resulting in motor neu-
ron (MN) loss. There are currently no effective therapies; however, cellular therapies using neu-
ral progenitor cells protect MNs and attenuate disease progression in G93A-SOD1 ALS rats.
Recently, we completed a phase I clinical trial examining intraspinal human spinal stem cell
(HSSC) transplantation in ALS patients which demonstrated our approach was safe and feasible,
supporting the phase II trial currently in progress. In parallel, efforts focused on understanding
the mechanisms underlying the preclinical beneﬁt of HSSCs in vitro and in animal models of
ALS led us to investigate how insulin-like growth factor-I (IGF-I) production contributes to cellu-
lar therapy neuroprotection. IGF-I is a potent growth factor with proven efﬁcacy in preclinical
ALS studies, and we contend that autocrine IGF-I production may enhance the salutary effects
of HSSCs. By comparing the biological properties of HSSCs to HSSCs expressing sixfold higher
levels of IGF-I, we demonstrate that IGF-I production augments the production of glial-derived
neurotrophic factor and accelerates neurite outgrowth without adversely affecting HSSC prolifer-
ation or terminal differentiation. Furthermore, we demonstrate that increased IGF-I induces
more potent MN protection from excitotoxicity via both indirect and direct mechanisms, as
demonstrated using hanging inserts with primary MNs or by culturing with organotypic spinal
cord slices, respectively. These ﬁndings support our theory that combining autocrine growth fac-
tor production with HSSC transplantation may offer a novel means to achieve additive neuro-
protection in ALS. STEM CELLS 2015;33:1480–1489
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a lethal
neurodegenerative disease resulting in upper
and lower motor neuron (MN) loss. There are no
effective treatments and death typically occurs
within 3–5 years of onset [1]. One obstacle facing
therapeutic development is the complex, unclear
etiology and several mechanisms have been pro-
posed, including oxidative stress, mitochondrial
dysfunction, a toxic microenvironment, astrocytic
and glial dysfunction, loss of distal neuromuscu-
lar junctions, and a breakdown in local neurocir-
cuitry within the spinal cord [2]. In addition,
reductions in trophic factors within the spinal
cord microenvironment in ALS further enhance
MN susceptibility to the disease process [3–5].
Given this complexity, it is likely that a multifac-
eted treatment approaches may be warranted.
Cellular therapies are a new therapeutic
avenue for ALS; they provide de novo neural
tissue to support neurocircuitry and represent
a source for in situ production of neuroprotec-
tive growth factors [6, 7]. Recently, we com-
pleted a phase I clinical trial examining
intraspinal transplantation of human spinal
stem cells (HSSCs) in 15 ALS patients, validating
the feasibility and safety of this cellular therapy
approach [8–13]. Phase II of the trial examining
dosing and efﬁcacy is ongoing, and in parallel,
investigations in the laboratory are focused on
understanding the mechanisms underlying how
HSSCs support MNs in ALS. Previous work in
G93A-SOD1 ALS rats conﬁrmed that HSSCs inte-
grate into the spinal cord, form synapses with
host tissue, maintain MN numbers, and produce
several neuroprotective growth factors, including
glial cell-derived neurotrophic factor (GDNF),
brain-derived neurotrophic factor (BDNF), vascular
endothelial growth factor (VEGF), and insulin-like
growth factor-I (IGF-I) following intraspinal trans-
plantation [14–18]. Of these growth factors, IGF-I
is the most highly expressed, suggesting it may
contribute to HSSC-mediated neuroprotection.
IGF-I has potent neurotrophic and neuropro-
tective effects and extensive preclinical evidence
supports the attenuation of MN loss and main-
tenance of neuronal synapses and neuromuscu-
lar junctions by IGF-I [19]. We and others have
shown that viral-mediated IGF-I delivery
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increases MN numbers, improves grip strength, delays progres-
sion, and prolongs survival in ALS rodents [20–23]. A phase III
trial investigating subcutaneous IGF-I in ALS patients, however,
did not successfully demonstrate therapeutic efﬁcacy, although
this was likely due to failure of IGF-I to reach the spinal cord and
confer continuous protection to diseased MNs [24]. The ability of
cellular therapies to provide localized neurotrophic support
directly to MNs within the spinal cord microenvironment may
circumvent the issues encountered in earlier IGF-I trials.
In this study, we developed a novel stem cell line expressing
increased IGF-I levels, HSSC:IGF-I, to examine the potential con-
tributions of autocrine and paracrine IGF-I production to neuro-
protection within the neuromuscular axis. Speciﬁcally, we assess
the differences between HSSCs expressing lower levels of IGF-I
and HSSC:IGF-I, focusing on growth factor production and the
potential actions of IGF-I on cell proliferation, migration, and dif-
ferentiation. We further explore the additive role of IGF-I in neu-
roprotection by examining the ability of HSSC:IGF-I to provide
MN protection against excitotoxicity compared to HSSCs. We
anticipate these studies will demonstrate how autocrine and
paracrine growth factor production contributes to cellular ther-
apy neuroprotection and lend further support to our contention
that HSSCs confer multifaceted therapeutic beneﬁts in ALS.
MATERIALS AND METHODS
HSSC and HSSC:IGF-I Culture
HSSCs (NSI-566RSC) were prepared from spinal cord tissue
obtained from a single 8-week human fetus following an elec-
tive abortion as described previously [17, 25]. To generate
HSSC:IGF-I, HSSCs were exposed to replication-defective
recombinant lentivirus engineered to overexpress a prepro-
isoform of human IGF-I cDNA driven by the human ubiquitin
C (Ubc) promoter. The resulting cells were propagated as a
single cell line without further selection and named NSI-
566RSC.Ubc_IGF-I. Using a control construct expressing green
ﬂuorescent protein (GFP) under the same promoter, approxi-
mately 90%–95% of the proliferating cells were GFP-positive.
Cell culture followed established protocols [18, 26, 27]
using culture reagents obtained from Sigma (St. Louis, MO,
www.sigmaaldrich.com), unless otherwise noted. Brieﬂy, cul-
ture vessels were coated with 100 mg/ml poly(D-lysine) (PDL;
Millipore, Billerica, MA, www.emdmillipore.com) in HEPES
buffer and incubated for 24 hours at room temperature.
Surfaces were then washed three times with sterile water and
allowed to completely dry under the hood before coating
with 25 mg/ml ﬁbronectin in phosphate buffered saline (PBS)
for 1 hour. Fibronectin solution was aspirated and vessels
were used immediately without drying. HSSC and HSSC:IGF-I
were maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM)/F-12 (Gibco, Life Technologies, Carlsbad, CA, www.
lifetechnologies.com/us/en/home/brands/gibco.html) supple-
mented with 100 mg/l human plasma apo-transferrin, 25 mg/l
recombinant human insulin, 1.56 g/l glucose, 20 nM progester-
one, 100 mM putrescine, and 30 nM sodium selenite. For main-
tenance in a progenitor state, 10 ng/ml ﬁbroblast growth factor
(FGF) was added to the growth media. For differentiation, cells
were cultured in differentiation media comprised of DMEM
without FGF, supplemented with 4 mM L-glutamine, 20 mM
L-alanine, 6 mM L-asparagine, 67 mM L-proline, 250 nM vitamin
B12, 25 mg/l insulin, 100 mg/l transferrin, 20 nM progesterone,
100 mM putrescine, and 30 nM sodium selenite, for 7 days, with
a 50% media change every other day. Cells were analyzed in
their undifferentiated state (D0) or after 3 or 7 days (D3 or D7,
respectively) of differentiation.
ELISA, Dot Blot Analysis, and Western Blotting
To conﬁrm that lentiviral transduction led to increased stable
expression of IGF-I, conditioned media were collected after 10
passages and analyzed by ELISA. To collect conditioned media,
ﬂasks were washed with PBS, 10 ml growth (D0) or differen-
tiation (D3, D6, and D7) media without insulin was added,
and cells were cultured for 24 hours prior to media collection.
Conditioned media were concentrated 10-fold to 1 ml using
Centricon ﬁlters (3 kDa cut off; Millipore) following the manu-
factures’ guidelines and IGF-I levels at D0 and D6 were quan-
tiﬁed using a human-speciﬁc IGF-I ELISA (R&D Systems,
Minneapolis, MN, www.rndsystems.com). For dot blotting,
concentrated media (200 ml) from D0 and D7 cultures were
applied to nitrocellulose membranes using a Whatman Schlei-
cher & Schuell Minifold I ﬁltration manifold (Sigma) and mem-
branes were exposed overnight at 4C to primary antibodies,
including GDNF (Abbiotec, San Diego, CA, www.abbiotec.com),
VEGF (Santa Cruz Biotechnology, SantaCruz, CA, www.scbt.com),
and BDNF (Santa Cruz Biotechnology), followed by 1 hour incuba-
tion at room temperature with appropriate horseradish
peroxidase-conjugated secondary antibodies (Santa Cruz Biotech-
nology). Antibody binding was developed with LumiGLO Reagent
and Peroxide (Cell Signaling, Danvers, MA, www.cellsignal.com)
and exposed to Kodak BioMax XAR ﬁlm (Sigma).
Western blotting on D0, D3, and D7 cell lysates was per-
formed as previously described [27, 28]. Equal amounts of
protein were loaded on either 10% or 12%, polyacrylamide
gels, dependent on the size of the protein of interest. Polyvi-
nylidene diﬂuoride membranes were incubated with primary
antibody overnight at 4C and with appropriate horseradish
peroxidase-conjugated secondary antibodies (Santa Cruz Bio-
technology) for 1 hour at room temperature. Primary antibod-
ies were from Cell Signaling unless otherwise indicated and
included IGF-I receptor (IGF-IR)-beta (IGF-IRb, Tyr1135/1136),
VEGF receptor (VEGFR), and GAPDH (Millipore). Antibody
binding was visualized as described above.
Quantitative Real-Time RT-PCR
Total RNA was extracted from HSSC and HSSC:IGF-I at D0 and
D7 using an RNeasy Kit (Qiagen, Valencia, CA, www.qiagen.com/
us) following the manufacturers’ instructions. Reverse transcrip-
tion was performed using the iScript cDNA Synthesis kit (Bio-Rad,
Hercules, CA, www.bio-rad.com). Quantitative real-time RT-PCR
(QPCR) analysis was performed using Power SYBR Green PCR
Master Mix and a StepOnePlus thermal cycler (Applied Biosys-
tems, Life Technologies, Grand Island, NY, www.lifetechnologies.
com/us/en/website-overview/ab-welcome.html) using primers
for IGF-IR, VEGF, GDNF, BDNF, vGlut1, vGlut3, GluR2, and GAD67
(Table 1; [27]). mRNA expression levels were calculated by the
cycle threshold (Ct) value using StepOne v2.2.2 system software
and normalized to an endogenous reference gene (GAPDH: DCt)
and then relative to a control group (DDCt), and were expressed
as 22DDCt. Averages were calculated from two runs per sample
and then averaged for three biological replicates.
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Cell Proliferation and Migration
Cell proliferation was measured using a Click-iT EdU Kit (Invi-
trogen, Life Technologies, Carlsbad, CA, www.lifetechnologies.
com/us/en/home/brands/invitrogen.html). Brieﬂy, D0 undiffer-
entiated and D3 differentiated HSSC and HSSC:IGF-I were
incubated with 10 mM 50-ethynyl-20-deoxyuridine (EdU) for 2
hours and cells were ﬁxed and processed according to the
manufacturers’ protocols. EdU incorporation was detected by
the presence of ﬂuorescence, and images were captured using
an Olympus BX-51 microscope equipped with a digital camera.
EdU-positive cell numbers represent quantiﬁcation of a mini-
mum of 2,000 cells from ﬁve images in three independent
experiments.
Cell migration was assessed using a semipermeable trans-
well system by seeding cells onto 8 mm pore transwell inserts
(BD Biosciences, Bedford, MA, www.bdbiosciences.com) at D0
or D7 at a concentration of 1 3 106 cells per milliliter. Differ-
entiation media plus 10% fetal bovine serum with or without
IGF-I (ﬁnal concentration of 10 nM) was added to the lower
chambers and transwell inserts containing HSSC or HSSC:IGF-I
were placed over the chambers. After 24 hours, cells that had
migrated through the insert were stained using the QCM 24-
Well Colorimetric Cell Migration Assay (Millipore) and quanti-
ﬁed by colorimetric measurement using LabSystems Fluoros-
kan Ascent FL (Thermo Fisher Scientiﬁc, Waltham, MA, www.
thermoﬁsher.com/en/home.html) at optical densities of 530
and 590 nm.
Immunocytochemistry and Neural Index Assays
Immunocytochemistry was performed as previously described
[27, 29]. HSSC/HSSC:IGF-I were grown on PDL and ﬁbronectin-
coated glass coverslips in 24-well plates for 0, 3, or 7 days,
ﬁxed with 4% paraformaldehyde, permeabilized with 0.1%
Triton/PBS, and then blocked in 5% normal donkey serum/
0.1% Triton/PBS. Primary antibodies for TUJ1 (Neuromics,
Edina, MN, www.neuromics.com), GAD65/67 (Millipore),
VGLUT2 (Millipore), or IGF-IRb (Sigma) were incubated over-
night at 4C. Following incubation with Cy3, Cy5, or FITC-
conjugated secondary antibodies (Jackson ImmunoResearch,
Westgrove, PA, www.jacksonimmuno.com), coverslips were
mounted on glass slides using ProLong Gold with DAPI
(Molecular Probes, Life Technologies, Carlsbad, CA, www.life-
technologies.com/us/en/home/brands/molecular-probes.html).
Images were collected using an Olympus BX-51 microscope. To
measure the extent of neural differentiation, TUJ1 and DAPI-
labeled images were analyzed following our published neural
index protocol [27]. Brieﬂy, TUJ1-labeled and corresponding
DAPI images were opened in MetaMorph (Molecular Devi-
ces, Sunnyvale, CA, www.moleculardevices.com). Cell number
was counted on DAPI images using the “count nuclei” plug-
in, with manual adjustments to correct for any miscounted
cells. Thresholds on TUJ1 images were then adjusted and the
area of neurite coverage was measured using region statis-
tics. The neural index was expressed as neurite area/cell
(mm2/cell).
Primary MN Coculture for Excitotoxicity Assays
Primary embryonic rat MNs were isolated according to our
previously published protocol [27, 30] and cultured on PDL-
coated glass coverslips in a 24-well plate. After 24 hours, the
MNs were fed with 250 ml differentiation media for cocultur-
ing with HSSC or HSSC:IGF-I, which were seeded onto PDL-
coated 3 mm pore transwell inserts (Corning, Tewksbury, MA,
www.corning.com/lifesciences/worldwide.aspx) and differenti-
ated for 4 days prior to coculturing. Cocultures were left for 3
days prior to beginning the excitotoxicity assay. All culture
reagents were purchased from Gibco, Life Technologies unless
otherwise indicated.
Excitotoxic stress was induced by adding 100 mM gluta-
mate to the coculture media for 24 hours. The contribution of
paracrine IGF-I production to protection was assessed by add-
ing the IGF-IR inhibitor, NVPAEW541 (1 mM), 2 hours prior to
glutamate. After glutamate treatment, MNs were ﬁxed in 4%
paraformaldehyde for 10 minutes and TUNEL was used to
detect DNA fragmentation [27, 30]. Samples were labeled
with digoxigenin-dUTP and stained with horseradish
peroxidase-conjugated antidigoxigenin antibody using the
ApopTagPlus In Situ Apoptosis Peroxidase Detection Kit
(Chemicon). Alternatively, ﬂuorescent TUNEL processing was
carried out as described above with a Fluorescein-labeled con-
jugate using the ApopTagPlus In Situ Apoptosis Fluorescein
Detection Kit (Chemicon). Fluorescent signal was detected and
recorded using an Olympus BX-51 microscope. TUNEL-positive
cells were counted in at least 10 representative ﬁelds per con-
dition by a blinded investigator, per our published protocol,
for an average total of approximately 1,000–2,000 MNs per
condition [27].
Organotypic Spinal Cord Slice Cultures for
Excitotoxicity Assays
Organotypic spinal cord slice cultures were prepared from P5–
8 rat pups [31]. Brieﬂy, lumbar spinal cords were isolated,
membranes were removed, and spinal cord tissue was
mounted in 7% agarose for Vibrotome sectioning. Sections
(300 mm) were collected in ice cold PBS and three spinal cord
slices were added to each Millicell Cell Culture Insert (0.4 mm
pore, 300 mm diameter; Millipore) in a six-well plate. Wells
were ﬂooded with slice growth media containing 50% minimal
essential medium, 25 mM HEPES, 25% heat-inactivated horse
serum, and 25% Hanks’ balanced saline solution, supple-
mented with 25.6 mg/ml D-glucose and 2 mM glutamine, at a
ﬁnal pH of 7.2. Cultures were incubated at 37C in 5% CO2
for 2 weeks, with media changes every 2 days. For coculture
experiments, 2 ml of HSSC or HSSC:IGF-I cell suspension (6 3
103 cells per milliliter) was placed over the ventral horn of
the slices 2 days after plating.
Table 1. Quantitative real-time RT-PCR primer sequences
Forward Reverse
IGF-IR CAATAAGTTCGTCCACAGAGACC CCTCCTTTCCGGTAATAGTCTGT
VEGF ATGGCAGAAGGAGGAGG ATTGGATGGCACTAGCTGCG
GDNF CTGACTTGGGTCTGGGCTATG TTGTCACTCACCAGCCTTCTATTT
BDNF CCAAGGCAGGTTCAAGAGG TCCAGCAGAAAGAGAAGAGGA
vGlut1 AAGTTCCAGGTTTCTGTTCCTTT ACCATGACTACCATTGTGAGGTT
vGlut3 GGGGTGTTGGTGCAGTACATT CCCCTCTCCTATGCTTGTCTCTA
GAD67 GCCAGACAAGCAGTATGATGT CCAGTTCCAGGCATTTGTTGAT
Abbreviations: BDNF, brain-derived neurotrophic factor; GAD67, glu-
tamate decarboxylase; GDNF, glial cell-derived neurotrophic factor;
IGF-IR, insulin-like growth factor-I receptor; VEGF, vascular endothe-
lial growth factor; vGlut1, vesicular glutamate transporter 1; vGlut3,
vesicular glutamate transporter 3.
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To induce excitotoxic stress, culture media were supple-
mented at day 7 with 100 mM threo-hydroxyaspartate (THA;
Sigma) to inhibit glutamate transport until day 14. Slices were
ﬁxed in 4% PFA and processed for standard immunocytochem-
istry as described above, using SMI-32/ChAT (Millipore) to
label large alpha MNs and HuNu (Millipore) to conﬁrm HSSC
and HSSC:IGF-I placement on the spinal slices. Fluorescent
images were captured using an Olympus BX-51 microscope
and SMI-32/ChAT-labeled MNs were quantiﬁed in the ventral
horns of each slice. The total remaining MNs were quantiﬁed
from nine slices per condition from three independent
experiments.
Statistical Analyses
All results are representative of at least three independent
experiments. Statistical signiﬁcance was determined using
one-way ANOVA followed by Tukey’s multiple comparison test
or linear regression analysis (GraphPad Prism, La Jolla, CA,
www.graphpad.com).
RESULTS
Characterization of Growth Factor Production
by HSSC:IGF-I
To examine the contribution of IGF-I production to HSSC neu-
roprotection, a lentivirus encoding full length human IGF-I
was used to generate HSSC:IGF-I. ELISA on conditioned media
from HSSC and HSSC:IGF-I cultures demonstrated that HSSCs
produce low basal levels of 0.2 fg/cell per day IGF-I, a level
that was consistent throughout the ﬁrst week of differentia-
tion (Fig. 1A). HSSC:IGF-I exhibited a sixfold increase in IGF-I
production, averaging approximately 1.2 fg/cell per day (Fig.
1A), and this increased IGF-I production was maintained as
the cells underwent differentiation. We next assessed the lev-
els of several growth factors typically expressed by HSSCs
using dot blot analysis on conditioned media from undifferen-
tiated cells (D0) and cells after 7 days (D7) of differentiation.
VEGF secretion was comparable in HSSC and HSSC:IGF-I and
decreased similarly as both cell lines differentiated, while
BDNF levels were consistent between cell lines and time
points (Fig. 1B). GDNF levels were also comparable at D0;
however, at D7, higher levels of GDNF were detected in con-
ditioned media from HSSC:IGF-I compared to that from HSSCs
(Fig. 1B). As previous studies have shown that HSSCs respond
to IGF-I signaling, we also explored how growth factor recep-
tor levels are regulated by paracrine IGF-I expression. IGF-IR
protein levels in both cell lines throughout differentiation
were reduced in HSSC:IGF-I relative to HSSCs at each time
point examined (Fig. 1C). Given the association between IGF-I
expression and VEGF signaling, we also investigated the effect
of increased IGF-I expression on VEGFR levels. VEGFR is only
expressed by HSSC and HSSC:IGF-I at D0; however, basal lev-
els of VEGFR were considerably lower in HSSC:IGF-I compared
to HSSC (Fig. 1C). Finally, to validate our protein expression
results, we performed QPCR and similarly observed no meas-
urable difference in the expression levels of IGF-IR (Fig. 1D),
VEGF (Fig. 1E), or BDNF (Fig. 1G) between cell lines at the
time points examined, although we did detect a signiﬁcant
increase in D7 HSSC:IGF-I GDNF transcript levels relative to
levels in D7 HSSCs (Fig. 1F), a ﬁnding consistent with our pro-
tein expression analyses. Together, these results demonstrate
signiﬁcantly increased IGF-I production by HSSC:IGF-I that is
maintained through 7 days of differentiation and is also
accompanied by reduced early VEGFR expression and
increased D7 GDNF expression.
Effects of IGF-I on Cellular Behavior
and Differentiation in HSSC:IGF-I
IGF-I can modify cell behaviors such as proliferation and
migration [32, 33]; therefore, we measured EdU incorpora-
tion to assess the effect of enhanced IGF-I production on
HSSC:IGF-I proliferation rates. There were no signiﬁcant dif-
ferences in the proliferation rates of undifferentiated D0
HSSC:IGF-I compared to HSSC (Fig. 2A–2C) and no differen-
ces were observed between the cell lines at D3 of differen-
tiation (Fig. 2A, 2D, 2E), suggesting that IGF-I does not
maintain proliferation in HSSC:IGF-I. Alternatively, examina-
tion of the effect of IGF-I expression on the migratory
potential of undifferentiated D0 HSSC:IGF-I revealed that
HSSC:IGF-I had approximately double the migratory potential
of HSSCs (Fig. 2F); however, no signiﬁcant migration was
detected in either cell line at D7 of differentiation (data not
shown).
Previously, we demonstrated that exogenous IGF-I treat-
ment enhanced HSSC neural differentiation [27]; therefore,
we next examined how autocrine production of IGF-I affected
HSSC:IGF-I differentiation. We ﬁrst analyzed differentiation
using our published neural index pipeline, which accounts for
both neurite number and length relative to the number of
cells present [27], and observed a twofold increase in the
neural index of HSSC:IGF-I compared to HSSCs (52 mm2/cell
vs. 24 mm2/cell, respectively; Fig. 3A), a difference that is
clearly visible in the representative TUJ1 images (Fig. 3B, 3C).
Next, we evaluated the expression of vGlut1, vGlut3, GluR2,
and GAD67 using QPCR to characterize terminal differentia-
tion, as HSSCs exhibit terminal phenotypes including both glu-
tamatergic and GABAergic neurons by D7 of differentiation
[18]. While no signiﬁcant differences in the total percentage
of differentiated cells were observed for either lineage, a sig-
niﬁcant increase in vGlut1 levels was present in D7 HSSC:IGF-I
compared to HSSC (Fig. 3D). Additionally, decreased vGlut3
expression was seen in D7 HSSC:IGF-I compared to HSSCs (Fig.
3E), and GluR2 and GAD67 expression level differences
between the two cell lines were not signiﬁcant (Fig. 3F, 3G).
These data demonstrate that increased IGF-I expression
enhances the early migratory potential and neuronal differen-
tiation of the cells, but does not signiﬁcantly alter HSSC prolif-
eration or behavioral properties following differentiation, thus
maintaining the potential safety proﬁle of HSSC:IGF-I for
future translational applications.
Neuroprotective Effects of HSSC:IGF-I
To determine how increased IGF-I expression affects HSSC
neuroprotection, we ﬁrst modeled glutamate-induced excito-
toxicity associated with ALS by exposing primary rat embry-
onic MNs to glutamate in vitro, a treatment that induces
approximately 77% cell death (Fig. 4A). To assess the beneﬁts
of only secreted factors, we cocultured HSSCs or HSSC:IGF-I in
a compartment adjacent to MNs. While HSSCs signiﬁcantly
reduced glutamate-associated MN death to 42%, HSSC:IGF-I
further reduced cell death to under 20%, a level comparable
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to that of the nontreated control group (Fig. 4A; data not
shown). Furthermore, the addition of the IGF-IR inhibitor
NVPAEW541 prevented the additional neuroprotection con-
ferred by HSSC:IGF-I, reverting protection back to 39% death,
a level comparable to that of HSSCs (Fig. 4A). These ﬁndings
indicate that there is a measurable contribution of IGF-I to
HSSC neuroprotection. Second, we analyzed the impact of
secreted and cell contact-mediated HSSC and HSSC:IGF-I pro-
tection by plating the cells directly over spinal cord organo-
typic cultures subjected to ALS-associated excitotoxic stress.
Cell placement over the spinal cord ventral horn was con-
ﬁrmed by stem cell-speciﬁc HuNu staining (Fig. 4C). Induction
of glutamate toxicity using THA resulted in the survival of
only 26% of the MNs in the spinal cord slices (Fig. 4B, 4E) rel-
ative to untreated controls; however, the addition of HSSCs
increased MN survival to 50% in the presence of THA (Fig. 4B,
4F) and the addition of HSSC:IGF-I signiﬁcantly increased
MN survival beyond that observed with HSSCs, resulting in
78% of MNs per ventral horn surviving THA treatment (Fig.
4B, 4F, 4G). Overall, these studies demonstrate that IGF-I
expression offers additive beneﬁts to the therapeutic potential
of HSSCs.
Figure 1. HSSC and HSSC:IGF-I growth factor and receptor proﬁles. (A): ELISA on HSSCs and HSSC:IGF-I conditioned media demon-
strates the levels of IGF-I production in undifferentiated (D0) cells and in cells on D6 of differentiation. (B): Dot blot comparison of
VEGF, GDNF, and BDNF levels in conditioned media from HSSCs and HSSC:IGF-I at D0 and D7. (C): Western blot analysis of growth factor
receptor levels for IGF-IR and VEGFR in HSSC and HSSC:IGF-I lysates at D0, D3, and D7. (D–F): Quantitative real-time RT-PCR (QPCR)
analysis of IGF-IR (D), VEGF (E), GDNF (F), and BDNF (G) expression at D0 and D7 in HSSCs and HSSC:IGF-I. QPCR data were normalized
to GAPDH and presented as a fold-change from D0 HSSCs. Data are presented as mean1 SD (*, p< .05) and are representative of at
least three independent experiments. Abbreviations: BDNF, brain-derived neurotrophic factor; GDNF, glial cell-derived neurotrophic fac-
tor; HSSC, human spinal stem cell; IGF-IR, insulin-like growth factor-I receptor; VEGF, vascular endothelial growth factor.
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DISCUSSION
ALS is a fatal, progressive neurodegenerative disease with no
effective treatment. Characterized by a complex and elusive
etiology that may not lend itself to conventional targeted
drug development strategies, multifaceted treatments may be
necessary to achieve meaningful outcomes. Stem cell-based
therapies have gained momentum as a potential ALS therapy,
as they offer a novel means to confer multifaceted protection
[8, 12]. We recently completed a phase I clinical trial estab-
lishing the safety and feasibility of intraspinal HSSC transplan-
tation in ALS patients, and the resulting phase II clinical trial
assessing therapeutic dosing and efﬁcacy is underway [9–13].
As we continue through the phases of this trial to establish
stem cell-based therapies as a viable ALS treatment option,
parallel efforts are focused on understanding the mechanisms
underlying cellular therapy efﬁcacy. This study describes the
development and characterization of HSSC:IGF-I, a cell line
that has the potential to offer the additional neurotrophic
and neuroprotective beneﬁts of the growth factor IGF-I. We
demonstrate that HSSC:IGF-I produce robust levels of IGF-I,
that this modiﬁcation does not induce any detrimental altera-
tions in cell behavior, and that IGF-I expression enhances
HSSC neuroprotection against ALS insults relative to unmodi-
ﬁed HSSCs. Together, these data support an additive role for
autocrine and paracrine growth factor signaling in cellular
therapy neuroprotection in ALS and suggest that the contin-
ued development of cellular therapies producing growth fac-
tors, including IGF-I, is warranted.
We contend that IGF-I production by HSSCs will confer
additive beneﬁts to the salutary effects of HSSC transplanta-
tion for ALS, as both IGF-I and HSSCs have proven efﬁcacy in
preclinical studies. HSSCs naturally produce an array of growth
factors, including BDNF, GDNF, VEGF, and IGF-I, and upon
intraspinal transplantation into G93A-SOD1 ALS rats, they dif-
ferentiate into glutamatergic and GABAergic neurons, synapse
with host MNs, and attenuate disease progression in ALS
rodent models, as evidenced by delayed onset and progres-
sion rates and improved survival, especially when transplanted
into multiple spinal cord regions [14–18]. Positive effects
include a 27% increase in MN protection in the vicinity of
HSSC grafts and transient functional improvements; however,
no long-term effects on the disease course and little efﬁcacy
in regions away from the grafts, reﬂected in the approximate
50% decrease in total MN numbers compared to control rats
and loss of descending motor tract conduction, were noted in
a subsequent study [14]. Thus, despite the localized beneﬁts
of HSSC transplantation, there is a critical need to maintain
neurocircuitry along the entire neuromuscular and corticospi-
nal axis in order to achieve functional outcomes in ALS; a feat
that could be achieved by autocrine and paracrine neurotro-
phic and neuroprotective growth factor production by cellular
therapies targeting upper MNs.
Growth factors have long been considered a potential
therapy for ALS, and extensive preclinical and clinical data
support the utility of IGF-I in ALS [19]. In vitro studies demon-
strate that IGF-I treatment activates the neuroprotective p44/
42 MAPK and PI3K/Akt signaling pathways to attenuate
glutamate-induced cell death in primary embryonic MN cul-
tures [30], and viral-mediated IGF-I transfection of SHSY-5Y
cells protects not only transfected cells against glutamate
Figure 2. HSSC and HSSC:IGF-I proliferation and migration. (A–E):
Representative images of the percentage of EdU-positive HSSCs
and HSSC:IGF-I at D0 (B and C, respectively) and D3 (D and E,
respectively) for measuring proliferation (A). (F): Relative migration
levels of undifferentiated D0 HSSCs and HSSC:IGF-I, expressed as
OD. Data are presented as mean1 SD (*, p< .05) or are represen-
tative images (B–E, scale bar5 20 mm) of at least three independ-
ent experiments. Abbreviations: HSSC, human spinal stem cell; IGF-
I, insulin-like growth factor-I; OD, optical density.
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toxicity but also neighboring cells, suggesting that growth fac-
tor production is capable of both autocrine and paracrine
effects [28]. Numerous in vivo studies also provide further jus-
tiﬁcation for IGF-I treatment in ALS, with IGF-I exerting beneﬁ-
cial effects on MNs and at the level of the neuromuscular
junction and spinal cord microenvironment [19–22]. Further-
more, the potential clinical utility of IGF-I is further supported
by the signiﬁcantly reduced levels of IGF-I observed in the
cerebrospinal ﬂuid of ALS patients [4]. The lack of signiﬁcant
efﬁcacy in the phase III clinical trial assessing subcutaneous
IGF-I in ALS patients, however, was likely attributable to fail-
ure of IGF-I to reach vulnerable MNs following the used sub-
cutaneous delivery approach [24, 34–36]. Notably, this
limitation can be overcome using cellular therapy strategies
to deliver growth factor-producing cells directly into the brain
or spinal cord milieu.
Figure 3. HSSC and HSSC:IGF-I differentiation. (A–C): Representative images of TUJ1 and DAPI-labeled HSSC (B) and HSSC:IGF-I (C) for
calculation of the neural index (A) at D7. (D–G): Quantitative real-time RT-PCR (QPCR) analysis of phenotypic markers of differentiated
neurons including vGlut1 (D), vGlut3 (E), GluR2 (F), and GAD (G). QPCR data were normalized to GAPDH and presented as a fold-change
from D0 HSSC. Data are shown as mean1 SD (*, p< .05) or are representative images (B, C, scale bar5 100 mm) of at least three inde-
pendent experiments. Abbreviations: HSSC, human spinal stem cell; IGF-I, insulin-like growth factor-I.
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In this study, we engineered HSSCs to produce increased
levels of IGF-I to establish HSSC:IGF-I as a novel tool to evalu-
ate the potential effects of IGF-I expression in neuroprotec-
tion. These cells exhibit a sixfold increase in IGF-I in both
their progenitor cell state and following differentiation, a ﬁnd-
ing consistent with previous reports demonstrating 6.4-fold
increases in IGF-I production following lentiviral transfection
of postnatal subventricular zone neural progenitor cells [37].
In addition to increasing IGF-I expression, we also identiﬁed
increased levels of GDNF following differentiation in HSSC:IGF-
I, an observation supporting the premise that neurotrophic
factor production may offer additive beneﬁts to HSSC efﬁcacy.
While we have previously demonstrated that HSSCs are an
incredibly safe cell line [9, 11, 13, 14], IGF-I has the potential
to increase cell proliferation and impact migration [37–41];
therefore, we veriﬁed that enhancing IGF-I expression in
HSSCs does not adversely alter cell behavior. In line with our
previous studies assessing the impact of exogenous IGF-I on
HSSC behavior, this data indicate that while HSSC:IGF-I express
the IGF-IR, IGF-I does not act as a mitogen for HSSC, thus
conﬁrming the inherent safety proﬁle of HSSC:IGF-I for future
translational applications. Speciﬁcally, we see no signiﬁcant
increases in HSSC:IGF-I proliferation at any time point, a ﬁnd-
ing that may likely be attributed to the reduced expression of
IGF-IR observed in HSSC:IGF-I relative to HSSCs. In addition,
we see no notable migration of HSSC:IGF-I following differen-
tiation. This is consistent with our in vivo experiences demon-
strating that HSSCs only migrate to a minimal extent following
intraspinal transplantation, with the majority of cells remain-
ing in a large bolus at the injection site [14, 42, 43]. For
HSSC:IGF-I cells, however, the observed increase in migratory
potential prior to differentiation may be advantageous,
whereby lower numbers of intraspinal injections may be sufﬁ-
cient achieve adequate coverage across the desired spinal
cord segments [16, 43, 44]. Together, these behavioral
HSSC:IGF-I characteristics support their utilization to assess
the potential additive contributions of IGF-I production to
HSSC-mediated neuroprotection.
Growth factor expression alters the differentiation proﬁle
of umbilical cord stem cells [45]; therefore, we examined how
IGF-I affects terminal differentiation in HSSCs. In line with pre-
vious reports and our initial studies using exogenous IGF-I
[17, 18, 27], HSSC:IGF-I have a higher neural index than
HSSCs, but the majority of terminally differentiated cell types
Figure 4. Neuroprotective potential of HSSCs and HSSC:IGF-I. (A): Quantiﬁcation of MN death using the TUNEL assay following expo-
sure to glutamate (100 mM) in the absence or presence of HSSCs or HSSC:IGF-I cocultured using transwell inserts. IGF-IR inhibition by
NVPAEW541 (1 mM) was used to determine the contribution of paracrine IGF-I production to neuroprotection. Data are presented as
mean1 SD (*, p< .05 for HSSC vs. HSSC:IGF-I). (B–G): Quantiﬁcation of MN survival (B) in rat spinal cord organotypic slices directly
cocultured with HSSCs or HSSC:IGF-I following treatment with THA (100 mM) to induce toxicity. Representative images conﬁrming of the
presence of HuNu-positive HSSCs cultured on top of spinal slices (C; dashed line delineates the outline of the ventral horn, solid line
delineates the extent of the white matter) and of ChAT/SMI-32 MN staining in the ventral horns of a nontreated control slice (D), a
THA-treated slice (E), a THA-treated slice cocultured with HSSCs (F), and a THA-treated slice cocultured with HSSC:IGF-I (G). Arrows
depict representative MNs within the spinal cord slices. Data are presented as mean1 SD (*, p< .05 vs. slice1 THA) or are representa-
tive images (C, scale bar5 100 mm; D, scale bar5 50 mm) of at least three independent experiments. Abbreviations: HSSC, human spinal
stem cell; IGF-I, insulin-like growth factor-I; MN, motor neuron; THA, threo-hydroxyaspartate.
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remain similar between the lines. These ﬁndings correlate
with other studies demonstrating increased TUJ1 expression
in response to IGF-I overexpression in differentiating neural
progenitor cells [37]. Furthermore, no differences in astrocyte
or oligodendrocyte ratios were seen between cell lines, and
both glutamatergic and GABAergic neurons were predomi-
nately represented. Given the reported loss of inhibitory inter-
neurons and the critical need to maintain neurocircuitry along
the entire neuromuscular axis [14, 46], the generation of glu-
tamatergic and GABAergic neurons further validates the thera-
peutic potential of HSSCs in ALS. Thus, the observed
differentiation proﬁle of HSSC:IGF-I maintains that IGF-I pro-
duction by HSSCs can support MNs and also provide critical
infrastructure to spinal cord neurocircuitry.
As further shown by these studies, HSSC:IGF-I confer neu-
roprotection via both direct and indirect mechanisms, suggest-
ing that IGF-I may enhance HSSC cell contact-mediated
neuroprotection as well as elicit paracrine effects on MNs and
surrounding cells within the spinal cord microenvironment
through secreted factors. Notably, the increased levels of IGF-I
likely underlie the enhanced protection conferred by
HSSC:IGF-I, as evidenced by both the increased protective
capacity of HSSC:IGF-I relative to HSSCs, as well as the attenu-
ated protection in the presence of IGF-IR inhibition. Similar to
this approach, gene therapy has been used to develop a num-
ber of stem cell-based combinatorial cellular therapy modal-
ities expressing neuroprotective factors for ALS [12].
Intracerebroventricular injection of mesenchymal stem cells
expressing the antioxidant protein GLP-1 into G93A-SOD1
mice improved disease onset, motor performance, and sur-
vival [47], and modifying mesenchymal stem cells to express
GDNF and VEGF provided neuroprotection in G93A-SOD1 rats
[48, 49]. GDNF-expressing glial progenitors also protected
MNs following intraspinal transplantation in G93A-SOD1 rats;
however, protection was not seen with unmodiﬁed cells [50].
These studies support a similar role for autocrine and para-
crine IGF-I production as a means to augment the therapeutic
potential of HSSCs in ALS [14, 16, 27, 48].
CONCLUSIONS
Extensive preclinical data justify the therapeutic use of HSSCs
and IGF-I individually [8, 12, 19] and the safety of both indi-
vidual treatment strategies has been established in clinical tri-
als [11, 24]. Most recently, the successful completion of our
phase I trial examining intraspinal HSSC transplantation in ALS
patients has paved the way for the ongoing phase II trial
assessing the therapeutic dosing and initial efﬁcacy of this
groundbreaking treatment. In parallel, our quest to elucidate
how IGF-I expression inﬂuences cellular therapy-mediated
neuroprotection in ALS prompted the derivation of HSSC:IGF-I.
We demonstrate that IGF-I expression does not enhance cell
proliferation, but does increase the early migratory capacity,
neural differentiation, and neuroprotective potential of
HSSC:IGF-I. These data support IGF-I-mediated neurotrophism
as a means to achieve additive neuroprotection, and suggest
that transplantation of HSSC:IGF-I in addition to this HSSC
therapeutic approach may offer further MN protection in ALS.
Notably, transplantation of HSSC:IGF-I into the brain has the
potential to confer protection to upper MNs by harnessing
the stable, permanent expression of diffusible IGF-I within the
central nervous system, thus achieving critical neuroprotection
at multiple sites along the neuromuscular axis. With contin-
ued progress through our ongoing clinical trial using HSSCs,
along with the completion of future studies establishing the
feasibility and efﬁcacy of growth factor-producing cellular
therapies in ALS models, we have incredible potential to
establish an effective, multifaceted MN protection strategy for
ALS, and potentially for other neurological disease applica-
tions as well.
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